HomeDiscoveryPubblicazioniPubblicazioni 2008

Pubblicazioni 2008



The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, Debreczeni JE, Knapp S, Johnson LN
EMBO Journal
(2008) 27, 1907-1918

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases
Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH
(2008) 32(12), 1857-1865

Target validation and biomarker identification in Oncology; The example of Aurora kinases. Target validation to biomarker development; Focus on RNA interference.
Colombo R, Moll J
Molecular Diagnosis & Therapy
2008 (12), 63-60 & 71-76

Chapter 12. Basic Approaches to Gene/Exon Level Data Analysis: 3’IVT and Exon 1.0 ST Microarray Platforms
Bosotti R, Marchesi V, Calogero R
Chapter for a Book entitled: “Oligonucleotide Array Sequence Analysis” edited by Novascience
(2008) 12, 347-366

In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes
Quintieri L, Fantin M, Palatini P, De Martin S, Rosato A, Caruso M, Geroni C, Floreani M.
Biochemical Pharmacology
(2008) 76(6), 784-795

Cell proliferation method: click chemistry-based by BrdU coupling for multiplex antibody staining
Cappella P, Gasparri F, Pulici M, Moll J
Book Chapter “Current Protocols of Cytometry”
(2008) suppl 45, unit 7.34

High-content analysis of kinase activity in cells
Gasparri F, Sola F, Bandiera T, Moll J, Galvani A
Combinatorial Chemistry & High Throughput Screening
(2008) 11, 523-536

A novel method based on click chemistry, which overcomes limitations of cell cycle analysis by classical determination of BrdU incorporation, allowing multiplex antibody staining
Cappella P, Gasparri F, Pulici M, Moll J
(2008) 73 (7), 623-636

Occurrence and Modality of the Interaction between Brostallicin and the Human Glutathione S-transferases GSTP1-1 and GSTM2-2
Pezzola S, Turella P, Geroni C, Beria I, Colombo M, Mongelli N, Ricci G, MacArthur R, Federici G, Caccuri AM
J Biol Chem

Aurora kinase inhibitors: identification and preclinical validation of their biomarkers
Carpinelli P, Moll J
Expert Opin Ther Targets
(2008), 12 (1), 69-80

A Ccd7 kinase inhibitor restricts initiation of DNA replication ad has antitumor activity
Montagnoli A, Valsasina B, Menichincheri M, Croci V, Tibolla M, Tenca PL, Rainoldi S, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Bensimon A, Vanotti E, Santocanale C
Nature Chemical Biology
(2008) 4 (6), 357-365

Papeo GL, Posteri H, Vianello P, Varasi M
E.R.O.S. Encyclopedia of Reagents for Organic Synthesis
(2008), 1-6

First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Antitumor Agents. 1. Synthesis and Structure-Activity Relationships
Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, Cirla A, Cristiani C, D’Alessio R, Forte B, Martina K, Menichincheri M, Molinari A, Montagnoli A, Orsini P, Pillan A, Roletto F, Scolaro A, et al.
Journal of Medicinal Chemistry
(2008) 51, 487-501

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Brummendorf T J. Moll
(2008) 111(8), 4355-4364